

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4499998

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NOTICE OF SUCCESSION OF AGENCY FOR PATENT SECURITY INTEREST PREVIOUSLY RECORDED AT REEL/FRAME (035297/0945)

CONVEYING PARTY DATA

Name	Execution Date
UBS AG, STAMFORD BRANCH, AS PRIOR AGENT	06/20/2017

RECEIVING PARTY DATA

Name:	CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS SUCCESSOR AGENT
Street Address:	11 MADISON AVE.
Internal Address:	9TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10010

PROPERTY NUMBERS Total: 2

Property Type	Number
Patent Number:	8476471
Patent Number:	8258334

CORRESPONDENCE DATA

Fax Number: (650)251-5002
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (650) 251-5123
Email: jmull@stblaw.com
Correspondent Name: MARISSA LAMBERT
Address Line 1: 2475 HANOVER STREET
Address Line 4: PALO ALTO, CALIFORNIA 94304

ATTORNEY DOCKET NUMBER:	073310/0008
NAME OF SUBMITTER:	J. JASON MULL
SIGNATURE:	/J. Jason Mull/
DATE SIGNED:	07/12/2017

Total Attachments: 4

source=2. Patheon - Notice of Change of Agency Patent (Patheon API Services) - Execution Ver#page1.tif
 source=2. Patheon - Notice of Change of Agency Patent (Patheon API Services) - Execution Ver#page2.tif

source=2. Patheon - Notice of Change of Agency Patent (Patheon API Services) - Execution Ver#page3.tif
source=2. Patheon - Notice of Change of Agency Patent (Patheon API Services) - Execution Ver#page4.tif

NOTICE OF SUCCESSION OF AGENCY

This NOTICE OF SUCCESSION OF AGENCY (this “Notice”), dated as of June 20, 2017 (the “Effective Date”), is executed by UBS AG, STAMFORD BRANCH, in its capacity as Collateral Agent under the Original Agreements (as defined below) (the “Prior Agent”), and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, in its capacity as Collateral Agent under the Current Agreement (as defined below) (the “Successor Agent”).

WHEREAS, pursuant to that certain Credit Agreement, dated as of March 11, 2014, by and among Patheon Holdings I B.V. (f/k/a DPx Holdings B.V. and JLL/Delta Dutch Newco B.V.), a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands (the “Parent Borrower”), the other Credit Parties party thereto, the Prior Agent and certain other parties thereto (as amended, restated, amended and restated, supplemented and/or otherwise modified from time to time immediately prior to the Fourth Amendment Effective Date (as defined therein), the “Original Credit Agreement”), the Prior Agent and Patheon API Services Inc. (f/k/a IRIX Pharmaceuticals, Inc.) (the “Grantor”) entered into that certain U.S. Security Agreement, dated March 11 (as amended, modified, supplemented, restated or amended and restated), and Patent Short Form Security Agreement, dated as of March 31, 2015, pursuant to which the Grantor granted a security interest in and to certain collateral;

WHEREAS, the Patent Short Form Security Agreement was recorded with the United States Patent and Trademark Office on March 31, 2015 at Reel/Frame 035297/0945, with respect to the patents identified on Schedule A attached hereto;

WHEREAS, the Original Credit Agreement was amended as of April 20, 2017 (as the Original Credit Agreement, as amended, the “Current Agreement”), and in connection with the transactions under the Current Agreement, the Prior Agent, the Successor Agent, the Parent Borrower and certain other parties have entered into that certain Agency Resignation and Succession Agreement, dated as of April 20, 2017 (the “Resignation Agreement”), whereby the Prior Agent resigned as the Administrative Agent and as the Collateral Agent and is succeeded to and replaced by the Successor Agent as successor Administrative Agent and as successor Collateral Agent;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Resignation Agreement.
2. Succession and Replacement of Agency. Pursuant to the terms and conditions set forth in the Resignation Agreement, the Prior Agent has ceased to be Collateral Agent under such capacity and is succeeded to and replaced by the Successor Agent as Collateral Agent under such capacity. Nothing herein shall be deemed to terminate, interrupt or impair the continuity of the security interest in the collateral originally granted to the Prior Agent under the Patent Security Agreements, which security interest is now succeeded by and transferred to the Successor Agent.

IN WITNESS WHEREOF, the parties have executed this Notice effective as of the Effective
Date:


UBS AG, STAMFORD BRANCH,
as Existing Agent

By:  _____

Name: Darlene Arias

Title: Director

UBS AG, STAMFORD BRANCH,
as Existing Agent

By:  _____

Name: Kenneth Chin

Title: Director


**CREDIT SUISSE AG, CAYMAN ISLANDS
BRANCH,**
as Successor Agent


By: _____

Name:

Title:

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH,
as Successor Agent

By: 
Name: Mikhail Faybusovich
Title: Authorized Signatory

By: 
Name: Warren Van Heyst
Title: Authorized Signatory

[Notice of Succession of Agency]

PATENT
REEL: 043165 FRAME: 0985

Schedule A

Transfer of Patent Security Agreement recorded March 31, 2015 at Reel/Frame 035297/0945

	<u>Patent No.</u>	<u>Registered Owner</u>	<u>Issue Date</u>
SYNTHESIS OF PROSTANOIDS	8,476,471	IRIX Pharmaceuticals, Inc.	July 2, 2013
N-ALKANOYL- N,N',N'- ALKYLENEDIAMINE TRIALKANOIC ACID ESTERS	8,258,334	IRIX Pharmaceuticals, Inc.	September 4, 2012